/
ATRC
$28.70-$1.48 (-4.90%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.5B
51M shares
52-week range
$25.36 – $43.18
19% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-50.63
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201.6M | $230.8M | $206.5M | $274.3M | $330.4M | $399.2M | $465.3M | $534.5M |
| Cost of revenue | $54.5M | $60.5M | $57.2M | $68.5M | $84.4M | $98.9M | $117.8M | $136.8M |
| Gross profit | $147.1M | $170.3M | $149.3M | $205.9M | $245.9M | $300.4M | $347.5M | $397.7M |
| Gross margin | 73.0% | 73.8% | 72.3% | 75.0% | 74.4% | 75.2% | 74.7% | 74.4% |
| R&D | $34.7M | $41.2M | $43.1M | $48.5M | $57.3M | $73.9M | $96.2M | $90.2M |
| Operating income | −$17.1M | −$33.1M | −$44.2M | $55.2M | −$42.7M | −$26.7M | −$40.0M | −$3.4M |
| EBITDA | −$7.5M | −$21.5M | −$33.6M | $65.7M | −$29.5M | −$8.1M | −$18.5M | $16.2M |
| Net income | −$21.1M | −$35.2M | −$48.2M | $50.2M | −$46.5M | −$30.4M | −$44.7M | −$11.4M |
| Net margin | -10.5% | -15.2% | -23.3% | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% |
| EPS (diluted) | -0.62 | -0.94 | -1.14 | 1.09 | -1.02 | -0.66 | -0.95 | -0.24 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $605M | $0.04 | $0.03–$0.04 | 6 |
| 2027 | $678M | $0.36 | $0.31–$0.40 | 6 |
| 2028 | $763M | $0.60 | $0.40–$0.77 | 5 |
| 2029 | $847M | $0.73 | $0.72–$0.74 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
AtriCure, Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
www.atricure.com- Employees
- 1,350
- IPO / List date
- Aug 5, 2005
- HQ
- MASON, OH
Held by traders on TradeandTell
No one on the platform currently holds ATRC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 308,700 | $8.8M |
| Bridgewater Associatesas of 2026-03-31 | 33,517 | $956.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ATRC yet.
